These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23191935)

  • 1. Exenatide as a novel weight loss modality in patients without diabetes.
    Moreno JL; Willett KC; Desilets AR
    Ann Pharmacother; 2012 Dec; 46(12):1700-6. PubMed ID: 23191935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of metformin for weight management in patients without type 2 diabetes.
    Desilets AR; Dhakal-Karki S; Dunican KC
    Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.
    Su N; Li Y; Xu T; Li L; Kwong JS; Du H; Ren K; Li Q; Li J; Sun X; Li S; Tian H
    Int J Cardiol; 2016 Sep; 219():293-300. PubMed ID: 27343423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of pramlintide for weight loss.
    Dunican KC; Adams NM; Desilets AR
    Ann Pharmacother; 2010 Mar; 44(3):538-45. PubMed ID: 20164472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
    Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
    Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
    Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
    Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.
    Murphy CE
    Ann Pharmacother; 2012 Jun; 46(6):812-21. PubMed ID: 22669803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome.
    Liu X; Zhang Y; Zheng SY; Lin R; Xie YJ; Chen H; Zheng YX; Liu E; Chen L; Yan JH; Xu W; Mai TT; Gong Y
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):767-774. PubMed ID: 28834553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide: a new option for the treatment of type 2 diabetes.
    Yoo BK; Triller DM; Yoo DJ
    Ann Pharmacother; 2006 Oct; 40(10):1777-84. PubMed ID: 16985091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapeutic options for overweight adolescents.
    Dunican KC; Desilets AR; Montalbano JK
    Ann Pharmacother; 2007 Sep; 41(9):1445-55. PubMed ID: 17652127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance.
    Aronne LJ; Finer N; Hollander PA; England RD; Klioze SS; Chew RD; Fountaine RJ; Powell CM; Obourn JD
    Obesity (Silver Spring); 2011 Jul; 19(7):1404-14. PubMed ID: 21293451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in energy balance following exenatide administration.
    Bradley DP; Kulstad R; Racine N; Shenker Y; Meredith M; Schoeller DA
    Appl Physiol Nutr Metab; 2012 Oct; 37(5):893-9. PubMed ID: 22735035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide. Amylin/Eli Lilly.
    Giannoukakis N
    Curr Opin Investig Drugs; 2003 Apr; 4(4):459-65. PubMed ID: 12808888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.
    Dushay J; Gao C; Gopalakrishnan GS; Crawley M; Mitten EK; Wilker E; Mullington J; Maratos-Flier E
    Diabetes Care; 2012 Jan; 35(1):4-11. PubMed ID: 22040840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
    Nayak UA; Govindan J; Baskar V; Kalupahana D; Singh BM
    QJM; 2010 Sep; 103(9):687-94. PubMed ID: 20624837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.